Immunoassay Market to Reach $64.4 billion by 2035
Immunoassay market was valued at $37.6 billion in 2025 and is projected to reach $64.4 billion by 2035, growing at a CAGR of 5.6% during the forecast period (2026-2035). The sustained rise in infectious and chronic disease burden globally remains the most critical structural driver underpinning revenue generation in the immunoassay market. According to government-backed data from the World Health Organization (WHO), noncommunicable diseases account for approximately 41 million deaths annually, representing nearly 74% of all global deaths, while infectious diseases such as tuberculosis, HIV, hepatitis, and emerging viral outbreaks continue to require continuous large-scale screening and monitoring programs. This epidemiological landscape directly translates into recurring demand for immunoassay-based diagnostics, particularly for antigen-antibody detection workflows used in routine screening, disease progression monitoring, and therapeutic response assessment. In parallel, national public health agencies such as the Centers for Disease Control and Prevention (CDC) continue to expand disease surveillance and laboratory testing infrastructure, reinforcing the role of immunoassays as a core diagnostic modality within standardized testing protocols.
Browse the full report description of “Immunoassay Market Size, Share & Trends Analysis Report by Product Type (Reagents & Kits, Analyzers/Instruments, and Software & Services), by Technology (Enzyme-Linked Immunosorbent Assay (ELISA), Chemiluminescence Immunoassay (CLIA), Fluorescence Immunoassay (FIA), Radioimmunoassay (RIA), Lateral Flow Immunoassay (LFIA), and Multiplex Immunoassay), by Application (Infectious Diseases, Oncology, Cardiology, Endocrinology, Autoimmune Diseases, Therapeutic Drug Monitoring (TDM), Allergy Testing, and Others), by End-User (Hospitals & Clinics, Diagnostic Laboratories, Academic & Research Institutes, Home Care, and Other), Forecast Period (2026–2035)” at https://www.omrglobal.com/industry-reports/immunoassay-market
From a revenue standpoint, this driver is highly defensible as it aligns with how money is actually earned in the market, primarily through high-frequency reagent and consumable usage linked to testing volumes rather than one-time instrument sales. Infectious disease diagnostics alone accounted for a significant share of in-vitro diagnostic demand, with immunoassay technologies contributing over 35% of revenue within infectious disease testing workflows, reflecting their widespread adoption across centralized laboratories and point-of-care settings. The continuous expansion of screening programs, including routine testing for infectious diseases, oncology biomarkers, and endocrine disorders, ensures predictable and recurring revenue streams for manufacturers. This demand pattern is further reinforced by government-led initiatives aimed at early diagnosis and disease management, particularly in emerging economies where testing penetration is still expanding. As a result, the increasing disease burden does not merely support market growth at a conceptual level but directly drives repeat purchase cycles of assay kits and reagents, making it the single most important variable in estimating and validating the size of the global immunoassay market.
Innovation Leaders Transforming the Immunoassay Market
The key players in the immunoassay market include Abbott Laboratories, F. Hoffmann-La Roche Ltd, Siemens Healthineers AG, Danaher Corporation, Thermo Fisher Scientific Inc., among others.
- In November 2025, Shanghai Kehua Bio-engineering Co., Ltd. (KHB) showcased its latest compact chemiluminescence platform the Polaris V150 Automatic Chemiluminescence Immunoassay Analyzer at MEDICA 2025, one of the world’s leading medical industry exhibitions. As a featured product at this year’s KHB booth, the Polaris V150 demonstrates the company’s continuous innovation in automated diagnostics.
- In April 2025, Labcorp announced the nationwide launch of its pTau-217/Beta Amyloid 42 Ratio, a powerful new blood-based biomarker test to aid in the diagnosis of Alzheimer's disease. The new test further expands Labcorp's leading blood-based biomarker portfolio for Alzheimer's disease and dementia.
Market Coverage
- The market number available for – 2025-2035
- Base year- 2025
- Forecast period- 2026-2035
- Segment Covered-
- By Product Type
- By Technology
- By Application
- By End-User
- Regions Covered-
- North America
- Europe
- Asia-Pacific
- Rest of the World
- Competitive Landscape Abbott Laboratories, F. Hoffmann-La Roche Ltd, Siemens Healthineers AG, Danaher Corporation, Thermo Fisher Scientific Inc., among others.
Key questions addressed by the report.
- What is the market growth rate?
- Which segment and region dominate the market in the base year?
- Which segment and region will project the fastest growth in the market?
- Who is the leader in the market?
- How are players addressing challenges to sustain growth?
- Where is the investment opportunity?
Global Immunoassay Market Report Segment
By Product Type
- Reagents & Kits
- Analyzers/Instruments
- Software & Services
By Technology
- Enzyme-Linked Immunosorbent Assay (ELISA)
- Chemiluminescence Immunoassay (CLIA)
- Fluorescence Immunoassay (FIA)
- Radioimmunoassay (RIA)
- Lateral Flow Immunoassay (LFIA)
- Multiplex Immunoassay
By Application
- Infectious Diseases
- Oncology
- Cardiology
- Endocrinology
- Autoimmune Diseases
- Therapeutic Drug Monitoring (TDM)
- Allergy Testing
- Others
By End-User
- Hospitals & Clinics
- Diagnostic Laboratories
- Academic & Research Institutes
- Home Care
- Other
Global Immunoassay Market Report Segment by Region
North America
- United States
- Canada
Europe
- UK
- Germany
- Italy
- Spain
- France
- Russia
- Rest of Europe
Asia-Pacific
- China
- India
- Japan
- South Korea
- Australia and New Zealand
- ASEAN Economies
- Rest of Asia-Pacific
Rest of the World
- Latin America
- Middle East & Africa
To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/immunoassay-market